LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
23.2.2021 01:33:00 EET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches Imperva for AWS to Help Organizations Protect Applications and APIs3.8.2026 15:00:00 EEST | Press release
Thales today announced the availability of Imperva for AWS, bringing its industry-leading web application firewall (WAF) to Amazon Web Services, Inc. (AWS) Marketplace as a SaaS offering. Built on key AWS services, Imperva for AWS helps organizations protect web applications and APIs against common cyber threats and malicious bot activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803503864/en/ ©Thales The 2026 Thales Bad Bot Report found that automated traffic now accounts for 53% of all internet requests, with 27% of bot attacks targeting APIs directly. As attackers increasingly bypass user interfaces to operate at machine speed, organizations need application security that can keep pace without adding complexity. Imperva WAF delivers enterprise-grade protection natively on Amazon CloudFront. Unlike legacy content delivery network WAFs that route traffic outside the cloud provider network, Imperva WAF deploys direc
MEX Exchange, Part of MultiBank Group Strengthens Leadership Team with Key Appointment3.8.2026 14:39:00 EEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803009139/en/ MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. With more than 20 years of experience across sales, business development and electronic trading, Bahuguna joins MEX Exchange with extensive expertise in electronic trading solutions spanning EMS, OMS, OTC and ECN technologies across the foreign exchange
NIQ Returns to IFA 2026 to Lead Industry Conversations on Growth, Innovation, AI and Consumer Transformation3.8.2026 13:45:00 EEST | Press release
As the Official Global Insights Partner of IFA Berlin 2026, NIQ (NYSE: NIQ) will continue to play a leading role shaping industry discussions , bringing together data, AI-driven intelligence, and human insight to illuminate the forces reshaping growth, innovation, and consumer behavior. Through executive keynotes, panel discussions, exclusive market intelligence, and strategic customer engagements (including participation in the IFA Retail Leaders Summit, the fourth NIQ Business Breakfast, and a dedicated SMB-focused event) NIQ will help translate rapid market change into actionable opportunity for the global technology ecosystem. Under this year’s IFA theme, “The Future Is Now,” NIQ will provide timely perspectives on the forces redefining consumer technology, home appliances, and retail—from AI-driven innovation and evolving shopper expectations to omnichannel transformation and emerging growth opportunities. As brands and retailers navigate economic uncertainty, shifting purchase be
Prodalim Reports Q2 2026 Results, with Continued Accelerated Growth in its Specialty Ingredients & Solutions Business3.8.2026 13:03:00 EEST | Press release
Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth, highlighted by the increasing contribution of our Specialized Ingredients Solutions (SIS) business. We are clearly seeing the results of the transformation we have been leading over the past year, with revenue from our Specialized Ingredients Solutions business more than doubling compared to the same period last year. The business now contributes approximately 40% of the Group's adjusted EBITDA. We expect this trend to continue gaining momentum, while maintaining the stability and strong performance of our Juice Solutions business. We continue to reinvest the benefits of our growth in strengthening our operational infrastructure, recruiting key talent, and advancing innovative products that are entering commercialization . We believe these investments create a strong foundation for significant operating leverage that has yet to be fully realized, and we expect this
Historic French Luxury Leather Goods House Moreau Paris Sold to Leading Manufacturer3.8.2026 12:00:00 EEST | Press release
ASTEREN announces that the Paris Commercial Court has approved the acquisition of Moreau Paris, one of France’s most prestigious luxury leather goods houses, by Cardinal Invest, owner of the French luxury manufacturer Groupe Lécuyer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803029803/en/ Paris flagship rue du Faubourg Saint-Honoré (source: Moreau Paris) The transaction concludes a competitive international sale process conducted under the supervision of the Paris Commercial Court and marks the beginning of a new chapter for one of the last independent historic Paris monogram houses. Led by judicial liquidator Pablo Castanon at ASTEREN, with Richard Morgan Advisory as financial advisor, the process launched in early June attracted substantial interest from trade and financial investors worldwide. The Court order signed on 29 July lays the foundations for renewed investment, international expansion and long-term indus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom